Birgit Schultes compensation by year
Intellia Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $475,000 |
| Bonus | $207,575 |
| Stock awards | $675,672 |
| Option awards | $371,701 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $10,135 |
| Total | $1,740,083 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Intellia Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-197283, and prior-year filings.
How this page was built: the Intellia Therapeutics, Inc. filed document, accession 0001193125-26-197283. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 37,600 | $338,024 | — |
| PSU | 15,309 | $137,628 | — |
| RSU | 14,697 | $132,126 | — |
| PSU | 9,400 | $84,506 | — |
| RSU | 5,890 | $52,951 | — |
| PSU | 5,511 | $49,544 | — |
| PSU | 4,417 | $39,709 | — |
| Option | 53,714 | — | $10.09 |
| Option | 694 | — | $40.75 |
| Option | 11,490 | — | $32.66 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Intellia Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Intellia Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Leonard | President, Chief Executive Officer | $5,063,899 |
| Edward Dulac | Executive Vice President, Chief Financial Officer and Treasurer | $2,168,505 |
| David Lebwohl | Executive Vice President, Chief Medical Officer | $1,984,724 |
| James Basta | Executive Vice President, General Counsel and Corporate Secretary | $1,846,597 |
| Birgit Schultes · this page | Executive Vice President, Chief Scientific Officer | $1,740,083 |
Birgit Schultes's compensation dossier, Intellia Therapeutics
You have read Birgit Schultes's totals and holdings. The dossier adds each equity grant Intellia Therapeutics disclosed for Birgit Schultes and Intellia Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Intellia Therapeutics compensation record
free company briefThis page is one person within Intellia Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Intellia Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Intellia Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Intellia Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.